Nom du produit:6-chloro-7H-purin-2-amine
IUPAC Name:6-chloro-7H-purin-2-amine
- CAS:10310-21-1
- Formule moléculaire:C5H4ClN5
- Pureté:98%
- Numéro de catalogue:CM105259
- Poids moléculaire:169.57
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:10310-21-1
- Formule moléculaire:C5H4ClN5
- Point de fusion:-
- Code SMILES:NC1=NC(Cl)=C2NC=NC2=N1
- Densité:
- Numéro de catalogue:CM105259
- Poids moléculaire:169.57
- Point d'ébullition:
- N° Mdl:MFCD00075252
- Stockage:Protect form light and store in a dry and close container at room temperature
Category Infos
- Purines
- Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
- purine wholesale
- Find trusted purine wholesaler. Any requirements and problems can ask us at any time.
- Nucleosides and Nucleotides
- Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.
- nucleoside manufacturer
- As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.
Column Infos
- Ibezapolstat
- Acurx announces successful FDA end-of-phase 2 meeting and phase 3 readiness for Ibezapolstat in the treatment of C. difficile infection. The successful meeting outcomes include reaching key elements of Phase 3 clinical trial program and a development plan of NDA filling. C. difficile infection (CDI) is a bacterial infection of the colon, and causes diarrhea and colitis.
Ibezapolstat is a novel antibacterial agent that acts specially on DNA pol IIIC enzyme through competitive inhibition of dGTP (guanosine analog). Ibezapolstat has been granted Fast Track Designation from the U.S. FDA.